AIM: To test the effects of pre- and post-transplant clinical covariates on post-transplant health-related quality of life (HRQOL) score profiles in liver transplant recipients. MATERIAL AND METHODS: HRQOL was measured before and after transplantation using the SF-36 Health Survey. Clinical data [diagnosis, model of end-stage liver disease (MELD) score, post-transplant rejection and infection episodes], pre-transplant functional performance (FP), and demographics were collected. Multivariate models for the eight SF-36 scales and two summary components were developed using multiple regression. Discriminant analysis was used to test whether the score profiles differentiated among recipients with and without hepatitis C virus (HCV) infection. RESULTS: 104 adults reported pre- and post-transplant HRQOL. Time post-transplant averaged 9+/-8 months (range 1-39). Scores on all SF-36 measures improved from pre- to post-transplant (p<0.001), and 7 of 10 models were significant (p<0.05). After controlling for pre-transplant HRQOL and time post-transplant, HCV infection had a negative effect on the role physical, bodily pain, and role emotional scales. History of a rejection episode had a negative effect on the bodily pain and vitality scales. MELD scores > or = 18 had a positive effect on the role physical scale. Pre-transplant FP and post-transplant infection episodes did not affect post-transplant HRQOL. HCV infection had a significant effect on the SF-36 score profile (canonical correlation=0.50; p<0.001). CONCLUSIONS: Pre-transplant HCV infection, MELD score, and post-transplant rejection episodes have significant independent effects on HRQOL after liver transplantation. Their specific effects vary among the individual SF-36 scales, and HRQOL score profiles differ among HCV+ and HCV- recipients.
AIM: To test the effects of pre- and post-transplant clinical covariates on post-transplant health-related quality of life (HRQOL) score profiles in liver transplant recipients. MATERIAL AND METHODS: HRQOL was measured before and after transplantation using the SF-36 Health Survey. Clinical data [diagnosis, model of end-stage liver disease (MELD) score, post-transplant rejection and infection episodes], pre-transplant functional performance (FP), and demographics were collected. Multivariate models for the eight SF-36 scales and two summary components were developed using multiple regression. Discriminant analysis was used to test whether the score profiles differentiated among recipients with and without hepatitis C virus (HCV) infection. RESULTS: 104 adults reported pre- and post-transplant HRQOL. Time post-transplant averaged 9+/-8 months (range 1-39). Scores on all SF-36 measures improved from pre- to post-transplant (p<0.001), and 7 of 10 models were significant (p<0.05). After controlling for pre-transplant HRQOL and time post-transplant, HCV infection had a negative effect on the role physical, bodily pain, and role emotional scales. History of a rejection episode had a negative effect on the bodily pain and vitality scales. MELD scores > or = 18 had a positive effect on the role physical scale. Pre-transplant FP and post-transplant infection episodes did not affect post-transplant HRQOL. HCV infection had a significant effect on the SF-36 score profile (canonical correlation=0.50; p<0.001). CONCLUSIONS: Pre-transplant HCV infection, MELD score, and post-transplant rejection episodes have significant independent effects on HRQOL after liver transplantation. Their specific effects vary among the individual SF-36 scales, and HRQOL score profiles differ among HCV+ and HCV- recipients.
Authors: S K Geevarghese; A E Bradley; J K Wright; W C Chapman; I Feurer; J L Payne; E B Hunter; C W Pinson Journal: Am J Surg Date: 1998-05 Impact factor: 2.565
Authors: Irene D Feurer; J Kelly Wright; Jerita L Payne; Adriana C Kain; Paul E Wise; Pamela Hale; William C Chapman; Theodore Speroff; C Wright Pinson Journal: J Gastrointest Surg Date: 2002 Jan-Feb Impact factor: 3.452
Authors: Sammy Saab; Ayman B Ibrahim; Alexander Shpaner; Zobair M Younossi; Cindy Lee; Francisco Durazo; Steven Han; Karl Esrason; Victor Wu; Jonathan Hiatt; Douglas G Farmer; R Mark Ghobrial; Curtis Holt; Hasan Yersiz; Leonard I Goldstein; Myron J Tong; Ronald W Busuttil Journal: Liver Transpl Date: 2005-02 Impact factor: 5.799
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: R A Fisher; J M Ham; A Marcos; M L Shiffman; V A Luketic; P M Kimball; A J Sanyal; L Wolfe; A Chodorov; M P Posner Journal: Transplantation Date: 1998-12-27 Impact factor: 4.939
Authors: J L Payne; K R McCarty; J G Drougas; W C Chapman; J K Wright; N Y Pinson; K E Beliles; V L Newsom; E B Hunter; D S Raiford; J A Awad; R F Burk; K L Donovan; D H Van Buren; C W Pinson Journal: Am Surg Date: 1996-04 Impact factor: 0.688